212 related articles for article (PubMed ID: 33654209)
1. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
Gionfriddo I; Brunetti L; Mezzasoma F; Milano F; Cardinali V; Ranieri R; Venanzi A; Pierangeli S; Vetro C; Spinozzi G; Dorillo E; Wu HC; Berthier C; Ciurnelli R; Griffin MJ; Jennings CE; Tiacci E; Sportoletti P; Falzetti F; de Thé H; Veal GJ; Martelli MP; Falini B
Leukemia; 2021 Sep; 35(9):2552-2562. PubMed ID: 33654209
[TBL] [Abstract][Full Text] [Related]
2. Dactinomycin in acute myeloid leukemia with NPM1 mutations.
Beziat G; Tavitian S; Bertoli S; Huguet F; Largeaud L; Luquet I; Vergez F; Rieu JB; Bories P; Delabesse E; Récher C
Eur J Haematol; 2020 Sep; 105(3):302-307. PubMed ID: 32452083
[TBL] [Abstract][Full Text] [Related]
3. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
Jain P; Kantarjian H; Patel K; Faderl S; Garcia-Manero G; Benjamini O; Borthakur G; Pemmaraju N; Kadia T; Daver N; Nazha A; Luthra R; Pierce S; Cortes J; Ravandi F
Leuk Lymphoma; 2014 Jun; 55(6):1337-44. PubMed ID: 24004182
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Ranieri R; Pianigiani G; Sciabolacci S; Perriello VM; Marra A; Cardinali V; Pierangeli S; Milano F; Gionfriddo I; Brunetti L; Martelli MP; Falini B
Leukemia; 2022 Oct; 36(10):2351-2367. PubMed ID: 36008542
[TBL] [Abstract][Full Text] [Related]
5. Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia.
Falini B; Brunetti L; Martelli MP
N Engl J Med; 2015 Sep; 373(12):1180-2. PubMed ID: 26376154
[No Abstract] [Full Text] [Related]
6. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
7. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
8. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Issa GC; Bidikian A; Venugopal S; Konopleva M; DiNardo CD; Kadia TM; Borthakur G; Jabbour E; Pemmaraju N; Yilmaz M; Short NJ; Maiti A; Sasaki K; Masarova L; Pierce S; Takahashi K; Tang G; Loghavi S; Patel K; Andreeff M; Bhalla K; Garcia-Manero G; Ravandi F; Kantarjian H; Daver N
Blood Adv; 2023 Mar; 7(6):933-942. PubMed ID: 36322818
[TBL] [Abstract][Full Text] [Related]
10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
11. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
[No Abstract] [Full Text] [Related]
12. Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
Jo SY; Park SH; Kim IS; Yi J; Kim HH; Chang CL; Lee EY; Cho YU; Jang S; Park CJ; Chi HS
Ann Lab Med; 2016 Sep; 36(5):399-404. PubMed ID: 27374703
[TBL] [Abstract][Full Text] [Related]
13. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
15. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Wass M; Göllner S; Besenbeck B; Schlenk RF; Mundmann P; Göthert JR; Noppeney R; Schliemann C; Mikesch JH; Lenz G; Dugas M; Wermke M; Röllig C; Bornhäuser M; Serve H; Platzbecker U; Foerster KI; Burhenne J; Haefeli WE; Müller LP; Binder M; Pabst C; Müller-Tidow C;
Leukemia; 2021 Mar; 35(3):701-711. PubMed ID: 32561840
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
17. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
18. [Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia].
Qin W; Chao HY; Cai XH; Lu XZ; Liu J; Wu P; Chen MY
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3152-3157. PubMed ID: 31694106
[No Abstract] [Full Text] [Related]
19.
Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
[TBL] [Abstract][Full Text] [Related]
20. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
